Moneycontrol Be a Pro
Get App
Last Updated : Jul 15, 2019 04:54 PM IST | Source: PTI

Takeda Pharmaceutical expands portfolio of rare disease therapies in India

Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease.

Takeda Pharmaceutical Company said on July 15 it has launched an enzyme replacement therapy portfolio for lysosomal storage disorders (LSD) in India, expanding its range of rare disease therapies in the country.

Under lysosomal storage disorders, India has been recording the prevalence of Hunter syndrome, Gaucher disease and Fabry disease, Takeda said in a statement.

To address these, Takeda brings to the market Idursulfase for Hunter syndrome, Velaglucerase Alfa for Gaucher disease and Agalsidase Alfa for Fabry disease, it added.

Close

"At Takeda, we are committed to patient care by developing innovative new medicines and making existing medicines more readily available," Takeda India Country Head Vineet Singhal said.

Japan-based Takeda focuses on research and development efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases.

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Jul 15, 2019 04:44 pm
Loading...
Sections
Follow us on
Available On